FindTrial
Sign In

Post Marketing Surveillance Study of Cuprimine

Post Marketing Surveillance Study of Cuprimine (MK-0172-001)

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT01374282
Enrollment
Unknown
Registered
2011-06-15
Start date
Unknown
Completion date
Unknown
Last updated
2015-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scleroderma

Brief summary

Cuprimine (penicillamine) was made available in the Philippines by the Sponsor under a Compassionate Special Permit issued by the Bureau of Food and Drugs. Physicians were able to request the drug for their patients from the Sponsor. A Clinical Study Report form was completed for each purchase of Cuprimine.

Interventions

DRUGCuprimine (penicillamine)

Dosage determined by the physician based on indication for treatment

Sponsors

Merck Sharp & Dohme LLC
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

\- None

Exclusion criteria

\- None

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026